Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT05868629

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-…

This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E m…

United States40 participantsStarted 2024-02-06

Treatment: Non-investigational

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-…

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-…

All recent trials (1 shown)